Parchment, Ralph E.

Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas

Kummar, S., Chen, A., Ji, J., Zhang, Y., Reid, J. M., Ames, M., Jia, L., Weil, M., Speranza, G., Murgo, A. J., et al. (2011) · Cancer Research

PARP inhibition in cancer therapyCancer therapeutics and mechanisms

Cited by 259

Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition

Rapisarda, A., Hollingshead, M., Uranchimeg, B., Bonomi, C. A., Borgel, S. D., Carter, J. P., Gehrs, B., Raffeld, M., Kinders, R. J., Parchment, R., et al. (2009) · Molecular Cancer Therapeutics

Cancer, Hypoxia, and MetabolismAngiogenesis and VEGF in Cancer

Cited by 171

Differential toxicity of camptothecin, topotecan and 9-aminocamptothecin to human, canine, and murine myeloid progenitors (CFU-GM) in vitro

Erickson-Miller, C. L., May, R. D., Tomaszewski, J., Osborn, B., Murphy, M. J., Page, J. G., & Parchment, R. E. (1997) · Cancer Chemotherapy and Pharmacology

Cancer therapeutics and mechanismsImmunotoxicology and immune responses

Cited by 111

Abstract 3616: Validation and fitness testing of a quantitative immunoassay for HIF1α in biopsy specimens

Park, S. R., Kinders, R. J., Khin, S., Hollingshead, M., Parchment, R. E., Tomaszewski, J. E., & Doroshow, J. H. (2012) · Cancer Research

Cancer, Hypoxia, and MetabolismClinical Laboratory Practices and Quality Control

Cited by 1